You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePropantheline
Accession NumberDB00782  (APRD00177)
TypeSmall Molecule
GroupsApproved
DescriptionA muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. [PubChem]
Structure
Thumb
Synonyms
Propantelina bromuro
Propantelina, bromuro de
Propanthelin bromid
Propantheline
Propanthéline, bromure de
Propanthelini Bromidum
External Identifiers
  • SC 3171
  • UNII-UX9Z118X9F
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pro-banthine Tablets 15mgTablet15 mgOralWellspring Pharmaceutical Canada Corp1994-12-312009-02-23Canada
Pro-banthine Tablets 7.5 mgTablet7.5 mgOralWellspring Pharmaceutical Canada Corp1994-12-312009-02-23Canada
Propanthel Tab 15mgTablet15 mgOralIcn Canada Ltd.1974-12-312005-04-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Propantheline BromideTablet, film coated15 mg/1OralWest Ward Pharmaceuticals Corp.1981-12-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ErcorilMedic
MethaphyllinSannova
Pro BanthinePfizer
ProkindBeacon
PropanlineChin Teng
PropanthelineShou Chan
SpasthelineSun
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Propantheline Bromide
50-34-0
Thumb
  • InChI Key: XLBIBBZXLMYSFF-UHFFFAOYSA-M
  • Monoisotopic Mass: 447.140906478
  • Average Mass: 448.393
DBSALT000225
Categories
UNII1306V2B0Q8
CAS number298-50-0
WeightAverage: 368.4892
Monoisotopic: 368.222568831
Chemical FormulaC23H30NO3
InChI KeyVVWYOYDLCMFIEM-UHFFFAOYSA-N
InChI
InChI=1S/C23H30NO3/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22/h6-13,16-17,22H,14-15H2,1-5H3/q+1
IUPAC Name
methylbis(propan-2-yl)[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium
SMILES
CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12)C(C)C
Pharmacology
IndicationFor the treatment of enuresis. It has also been used for hyperhidrosis, and cramps or spasms of the stomach, intestines or bladder.
Structured Indications
PharmacodynamicsPropantheline is an anticholinergic drug, a medication that reduces the effect of acetylcholine, a chemical released from nerves that stimulates muscles, by blocking the receptors for acetylcholine on smooth muscle (a type of muscle). It also has a direct relaxing effect on smooth muscle. Propantheline is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome. In addition, Propantheline inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions.
Mechanism of actionAction is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic).
TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M1Proteinyes
antagonist
HumanP11229 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationApproximately 70% of the dose is excreted in the urine, mostly as metabolites.
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Propantheline can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Propantheline.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Propantheline is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Propantheline is combined with Alphacetylmethadol.Experimental, Illicit
AmbenoniumThe therapeutic efficacy of Propantheline can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Propantheline.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Propantheline.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Propantheline.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Propantheline is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Propantheline.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Propantheline.Approved
BezitramideThe risk or severity of adverse effects can be increased when Propantheline is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Propantheline is combined with Biperiden.Approved
Botulinum Toxin Type APropantheline may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BPropantheline may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Propantheline is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Propantheline is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Propantheline is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Propantheline.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Propantheline is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Propantheline.Approved
CimetropiumPropantheline may increase the anticholinergic activities of Cimetropium.Experimental
CodeineThe risk or severity of adverse effects can be increased when Propantheline is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Propantheline can be decreased when used in combination with Coumaphos.Vet Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Propantheline is combined with Cyclopentolate.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Propantheline.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Propantheline can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Propantheline can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Propantheline is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Propantheline is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Propantheline is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Propantheline is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Propantheline can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dicyclomine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Propantheline is combined with Diphenoxylate.Approved, Illicit
DonepezilThe therapeutic efficacy of Propantheline can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Propantheline is combined with DPDPE.Investigational
DronabinolPropantheline may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Propantheline can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Propantheline can be decreased when used in combination with Edrophonium.Approved
EluxadolinePropantheline may increase the constipating activities of Eluxadoline.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Propantheline.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Propantheline is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Propantheline is combined with Etorphine.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Propantheline is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Propantheline can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Propantheline is combined with Fesoterodine.Approved
GalantamineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Propantheline.Approved
Ginkgo bilobaThe therapeutic efficacy of Propantheline can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Propantheline is combined with Glucagon recombinant.Approved
GlycopyrroniumPropantheline may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Propantheline is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Propantheline is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Propantheline is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Propantheline can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Propantheline.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Propantheline is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Propantheline.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Propantheline is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Propantheline.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Propantheline.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Propantheline.Approved
IsoflurophateThe therapeutic efficacy of Propantheline can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Propantheline.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Propantheline is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Propantheline is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Propantheline is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Propantheline is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Propantheline can be decreased when used in combination with Malathion.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Propantheline.Approved
MefloquineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Memantine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Propantheline is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Propantheline is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Propantheline can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Methantheline.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Propantheline.Approved
MetixeneThe risk or severity of adverse effects can be increased when Propantheline is combined with Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Propantheline.Approved
MianserinMianserin may increase the anticholinergic activities of Propantheline.Approved
MinaprineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Propantheline is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Propantheline is combined with Morphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Propantheline is combined with N-butylscopolammonium bromide.Vet Approved
NabilonePropantheline may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Propantheline is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Propantheline is combined with Normethadone.Approved, Illicit
NVA237The risk or severity of adverse effects can be increased when Propantheline is combined with NVA237.Investigational
OpiumThe risk or severity of adverse effects can be increased when Propantheline is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Propantheline is combined with Orphenadrine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Propantheline is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Propantheline is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Propantheline is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Propantheline.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Propantheline is combined with Pancuronium.Approved
PentazocineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Propantheline is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pethidine.Approved
PhysostigmineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Propantheline is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Propantheline.Approved
PiritramideThe risk or severity of adverse effects can be increased when Propantheline is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Propantheline.Approved
Potassium ChloridePropantheline may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Propantheline.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Propantheline is combined with Propiverine.Investigational
PyridostigmineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Propantheline.Approved
QuinidineThe risk or severity of adverse effects can be increased when Propantheline is combined with Quinidine.Approved
RamosetronPropantheline may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Propantheline is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propantheline.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Propantheline is combined with Scopolamine butylbromide.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Propantheline.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Propantheline is combined with Solifenacin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Propantheline is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Propantheline.Approved
TacrineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Propantheline is combined with Tapentadol.Approved
TiotropiumPropantheline may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Propantheline is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Propantheline is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Propantheline is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Propantheline can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Propantheline.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Propantheline.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Propantheline is combined with Trimethaphan.Approved
TropicamideThe risk or severity of adverse effects can be increased when Propantheline is combined with Tropicamide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Propantheline.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Propantheline is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Propantheline.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Propantheline is combined with Vecuronium.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesA03AB05A03CA34
AHFS Codes
  • 12:08.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9327
Blood Brain Barrier+0.9012
Caco-2 permeable+0.6808
P-glycoprotein substrateSubstrate0.7706
P-glycoprotein inhibitor INon-inhibitor0.8742
P-glycoprotein inhibitor IINon-inhibitor0.6149
Renal organic cation transporterInhibitor0.5354
CYP450 2C9 substrateNon-substrate0.7749
CYP450 2D6 substrateNon-substrate0.6028
CYP450 3A4 substrateSubstrate0.7332
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.867
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7234
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8167
BiodegradationNot ready biodegradable0.6006
Rat acute toxicity2.7150 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9055
hERG inhibition (predictor II)Non-inhibitor0.5772
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Gd searle llc
  • Shire development inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Heather drug co inc
  • Impax laboratories inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Tablicaps inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral15 mg
TabletOral7.5 mg
Tablet, film coatedOral15 mg/1
Prices
Unit descriptionCostUnit
Propantheline bromide powder7.77USD g
Propantheline Bromide 15 mg tablet0.76USD tablet
Propantheline 15 mg tablet0.6USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility7.22e-05 mg/mLALOGPS
logP2.66ALOGPS
logP0.36ChemAxon
logS-6.8ALOGPS
pKa (Strongest Acidic)18.1ChemAxon
pKa (Strongest Basic)-7.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.53 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity119.25 m3·mol-1ChemAxon
Polarizability40.87 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as xanthenes. These are polycyclic aromatic compounds containing a xanthene moiety, which consists of two benzene rings joined to each other by a pyran ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzopyrans
Sub Class1-benzopyrans
Direct ParentXanthenes
Alternative Parents
Substituents
  • Xanthene
  • Diaryl ether
  • Acyl choline
  • Choline
  • Benzenoid
  • Quaternary ammonium salt
  • Carboxylic acid ester
  • Oxacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic cation
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Lukacs VA, Korting HC: [Antiperspirants and deodorants--ingredients and evaluation]. Derm Beruf Umwelt. 1989 Mar-Apr;37(2):53-7. [PubMed:2656175 ]
  3. Saitoh H, Hasegawa N, Kawai S, Miyazaki K, Arita T: Interaction of tertiary amines and quaternary ammonium compounds with gastrointestinal mucin. J Pharmacobiodyn. 1986 Dec;9(12):1008-14. [PubMed:3572714 ]
  4. Trkulja V, Crljen-Manestar V, Banfic H, Lackovic Z: Involvement of the peripheral cholinergic muscarinic system in the compensatory ovarian hypertrophy in the rat. Exp Biol Med (Maywood). 2004 Sep;229(8):793-805. [PubMed:15337834 ]
  5. Mokry J, Nosalova G, Jakubesova M: Propantheline and in vitro reactivity of urinary bladder smooth muscle in guinea pigs. Bratisl Lek Listy. 2005;106(4-5):151-4. [PubMed:16080359 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11